Current insights in allergen immunotherapy

Publication date: February 2018
Source:Annals of Allergy, Asthma & Immunology, Volume 120, Issue 2
Author(s): Giovanni Passalacqua, Diego Bagnasco, Matteo Ferrando, Enrico Heffler, Francesca Puggioni, Giorgio Walter Canonica
ObjectiveAllergen-specific immunotherapy (AIT) in its subcutaneous and sublingual forms is currently a well-established and experimentally supported treatment for respiratory allergy and hymenoptera venom allergy. There have been advances in its use linked strictly to the advancement in the knowledge of the molecular mechanisms of allergy, the production of well-characterized extracts, and diagnostic techniques. The use of AIT in asthma and the application of new approaches are expanding. We briefly review the advances and concerns in the use of AIT.Data SourcesPubMed and Scopus.Study SelectionsThe most recent and clinically relevant literature was selected and reviewed.ResultsThe introduction of high-quality products supported by large dose-finding trials has yielded better defined indications, contraindications, and modalities of use. Some specific products in tablet form have recently been approved in the United States. Sublingual immunotherapy has been found to be effective in asthma, which until recently had been a matter of debate. Another promising therapy is oral and sublingual desensitization for food allergy, for which encouraging results have recently been reported. In the near future, other options will be available, including new routes of administration (intralymphatic and epicutaneous), allergoids, engineered allergens, and peptides. The use of component-resolved diagnosis techniques will further refine and target AIT prescriptions.ConclusionThis condensed and updated review shows that AIT remains a viable treatment option, especially after the introduction of standardized tablets for some allergens. Food allergy and new administration routes represent a promising expansion.



http://ift.tt/2FVuuwx